-
<![CDATA[Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD]]>
19 Dec 2025 21:56 GMT
… treating obesity directly. You know, in the past, we used to treat … the complications – sleep apnea, diabetes, hypertension, cardiovascular disease … broader acceptance of pharmacologic treatment, especially GLP-1s … that a medication that works …
-
The Future of Obesity Management: Bridging Pharmacologic Innovation and Public Health
19 Dec 2025 21:00 GMT
… type 2 diabetes, cardiovascular disease, and metabolic … treatment paradigms.
Incretin-Based Therapies: A Turning Point
Recent pharmacologic … healthcare infrastructure and medication access, prevention … ;www.fda.gov/drugs/postmarket-drug-safety- …
-
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
19 Dec 2025 19:15 GMT
… to cover antiobesity medications for the first … for accessible obesity treatments, as 40% … cardiovascular disease, hypertension, stroke, and other chronic conditions. Making innovative drugs … approaches both drug affordability and pharmaceutical production. The …
-
Value of Conventional Ultrasound Combined with Shear Wave Elastography for Sarcopenia in Patients with Cardiovascular Disease
18 Dec 2025 20:24 GMT
… increases the risk of developing from chronic diseases, such … type 2 diabetes, and cardiovascular diseases (CVD).4–6 These … VI, vastus intermedius; CVD, cardiovascular disease; ROI, region of interest.
… Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. …
-
Why cardiovascular disease and depression often develop together
18 Dec 2025 12:54 GMT
By clarifying how these diseases influence each other, we can design interventions that break the cycle of comorbidity rather than simply manage its consequences
Evangelos Andreakos
CVD is the leading cause of death worldwide, with 10.2 million people …
-
<![CDATA[FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH]]>
19 Dec 2025 00:19 GMT
… treatment options.”
Phase 3 Clinical Trial Program
The FDA … Trial Program, which included more than 2,900 participants with established cardiovascular disease … the scope of the development effort behind the approval … believed in the drug and worked tirelessly …
-
Stress heightens risk of cardiovascular disease in people with anxiety and depression
17 Dec 2025 16:47 GMT
… that are active against drug-resistant strains.
Today, … how one of the drugs was developed, through a new …
Stress heightens risk of cardiovascular disease in people with anxiety … treatments to see if stress-reduction therapies, anti-inflammatory medications, …
-
Accessible Healthcare: Nagaland, HLL Lifecare sign MoU for AMRIT pharmacy
18 Dec 2025 20:57 GMT
… Medicine and Reliable Implants for Treatment) Pharmacy in the State. The MoU … Medicine and Reliable Implants for Treatment) Pharmacy initiative is aimed at providing … and implants for the treatment of cancer, cardiovascular diseases and all other ailments …
-
AHN Study: Pelvic Floor Physical Therapy Adherence Higher for Overactive Bladder Patients Without Concurrent Prescription Medication
18 Dec 2025 20:31 GMT
… medical therapy. Pharmacotherapy options typically include either anticholinergic medication or beta … from the onset of treatment."
Treatment guidelines for OAB … and emergency care, trauma care, cardiovascular disease, organ transplantation, cancer care, …
-
Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia
18 Dec 2025 20:25 GMT
… trial efficacy and real-world clinical effectiveness, offering insights to guide treatment … obesity, hypertension, cardiovascular disease and cerebrovascular accidents. … contained pharmacy claims of antidiabetic medications for … . Saudi J Med Med Sci. 2023; …